BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 103 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 0.50 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $990,138 | +1.3% | 139,850 | +0.7% | 0.01% | 0.0% |
| Q2 2023 | $977,701 | -4.5% | 138,878 | +13.1% | 0.01% | -11.1% |
| Q1 2023 | $1,024,302 | -29.4% | 122,818 | -2.8% | 0.01% | -30.8% |
| Q4 2022 | $1,450,762 | +13.4% | 126,373 | +24.5% | 0.01% | +8.3% |
| Q3 2022 | $1,279,000 | +9.8% | 101,539 | -7.8% | 0.01% | +9.1% |
| Q2 2022 | $1,165,000 | +84.9% | 110,115 | -16.6% | 0.01% | +120.0% |
| Q1 2018 | $630,000 | +17.8% | 132,021 | +21.1% | 0.01% | +25.0% |
| Q4 2017 | $535,000 | +28.9% | 109,044 | +37.7% | 0.00% | +33.3% |
| Q3 2017 | $415,000 | +2.7% | 79,203 | +9.1% | 0.00% | 0.0% |
| Q2 2017 | $404,000 | +73.4% | 72,591 | -12.0% | 0.00% | +50.0% |
| Q1 2016 | $233,000 | -76.6% | 82,476 | -14.6% | 0.00% | -80.0% |
| Q4 2015 | $997,000 | – | 96,610 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |